Envisagenics
Envisagenics is an AI-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics. The company offers SpliceCore, a cloud-based platform that is experimentally validated to predict and prioritize RNA splicing events as therapeutic targets, using machine learning algorithms to analyze RNA sequencing data and identify disease-relevant splicing changes. The platform…
Funding snapshot
About
Envisagenics is an AI-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics. The company offers SpliceCore, a cloud-based platform that is experimentally validated to predict and prioritize RNA splicing events as therapeutic targets, using machine learning algorithms to analyze RNA sequencing data and identify disease-relevant splicing changes. The platform integrates bioinformatics, AI, and biological expertise to accelerate drug discovery for conditions driven by RNA splicing errors, including cancer, neurodegenerative diseases, and rare genetic disorders. Envisagenics leverages its proprietary technology to identify new therapeutic targets and develop RNA-based drug candidates, partnering with pharmaceutical companies to advance precision medicine approaches. Founded in 2014 and headquartered in Long Island City, New York, Envisagenics has raised approximately $46.8 million in Series B funding from investors including SV Angel, Dolby Family Ventures, Dynamk Capital, The Cosine Group, and Third Kind Venture Capital.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Sequencing Analysis,
Genomics > Enabling Technologies > Technology Platforms > RNA interference
Team background
College Wise > Technion Israel Institute Technology
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.